The combined therapy of down-regulation of methionine flux through MAT2A inhibition or methionine restriction and the inhibition of SLC family SLC7A6 would disrupt the high methionine consumption in cancer cells and preserve the function of CD8 + T cells, which indicates a promising clinical treatment option for cisplatin resistant bladder cancer cell patient. Here, MAT2A is linked to urinary bladder carcinoma.